首页 正文

METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours

{{output}}
Background: Preclinical studies have suggested that metformin has anti-tumour effects, likely due to blockage of mammalian target of rapamycin pathway through adenosine monophosphate-activated protein kinase and decreased insulin... ...